The results of the present study on patients’ derived ex-vivo NSCLC cultures, showing positive anti-tumor immune response induced by the triple combination of Ido-1, PD-L1 and MEK- inhibition, encourage further research in this setting, especially in model with mesenchymal and immune-resistant features. The gene discussed is MAP2K7; the disease is neoplasm.